MP Healthcare Venture Management
Home About Us Portfolio News Contact
HomeAbout UsPortfolioNewsContact
MP Healthcare Venture Management
Thrasos Announces Promising Results for Phase 2 THR-184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury (AKI).
Brennan CaruthersFebruary 29, 2016
Facebook0 Twitter LinkedIn0 Reddit 0 Likes
Previous

miRagen Therapeutics Initiates First Clinical Trial for MRG-106 in Lymphoma Patients.

Brennan CaruthersMarch 2, 2016
Next

F-star Enters into Collaborative Discovery & Development Agreement with AbbVie for Bispecific Antibodies in Immuno-oncology.

Brennan CaruthersJanuary 11, 2016

© 2010-2019 MP Healthcare Venture Management, Inc.
All Rights Reserved.

Privacy Policy | Terms of Use

About UsPortfolioNews Contact